ロード中...
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is a very rare and highly aggressive cancer of the pleura associated in most cases with asbestos exposure. To date, no really efficient treatments are available for this pathology. Recently, it has been shown that epigenetic drugs, particularly DNA me...
保存先:
| 出版年: | Clin Epigenetics |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006850/ https://ncbi.nlm.nih.gov/pubmed/29946373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0517-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|